Literature DB >> 26808377

Corticotropin-Releasing Hormone Receptor 2 Gene Variants in Irritable Bowel Syndrome.

Hazuki Komuro1, Naoko Sato1, Ayaka Sasaki1, Naoki Suzuki2, Michiko Kano1,3, Yukari Tanaka1,4, Yumi Yamaguchi-Kabata4,5, Motoyori Kanazawa1, Hitoshi Warita2, Masashi Aoki2, Shin Fukudo1,6.   

Abstract

BACKGROUND: Corticotropin-releasing hormone (CRH) plays an important role in the pathophysiology of irritable bowel syndrome (IBS) and regulates the stress response through two CRH receptors (R1 and R2). Previously, we reported that a CRHR1 gene polymorphism (rs110402, rs242924, and rs7209436) and haplotypes were associated with IBS. However, the association between the CRHR2 gene and IBS was not investigated. We tested the hypothesis that genetic polymorphisms and haplotypes of CRHR2 are associated with IBS pathophysiology and negative emotion in IBS patients.
METHODS: A total of 142 IBS patients and 142 healthy controls participated in this study. Seven single nucleotide polymorphisms (SNPs) of the CRHR2 gene (rs4722999, rs3779250, rs2240403, rs2267710, rs2190242, rs2284217, and rs2284220) were genotyped. Subjects' psychological states were evaluated using the Perceived-Stress Scale, the State-Trait Anxiety Inventory, and the Self-Rating Depression Scale.
RESULTS: We found that rs4722999 and rs3779250, located in intronic region, were associated with IBS in terms of genotype frequency (rs4722999: P = 0.037; rs3779250: P = 0.017) and that the distribution of the major allele was significantly different between patients and controls. There was a significant group effect (controls vs. IBS), and a CRHR2 genotype effect was observed for three psychological scores, but the interaction was not significant. We found a haplotype of four SNPs (rs4722999, rs3779250, rs2240403, and rs2267710) and two SNPs (rs2284217 and rs2284220) in strong linkage disequilibrium (D' > 0.90). We also found that haplotypes of the CRHR2 gene were significantly different between IBS patients and controls and that they were associated with negative emotion.
CONCLUSION: Our findings support the hypothesis that genetic polymorphisms and haplotypes of CRHR2 are related to IBS. In addition, we found associations between CRHR2 genotypes and haplotypes and negative emotion in IBS patients and controls. Further studies on IBS and the CRH system are warranted.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26808377      PMCID: PMC4726564          DOI: 10.1371/journal.pone.0147817

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

The stress response is an important mechanism that is indispensable for the maintenance of life. Corticotropin-releasing hormone (CRH) is released from the paraventricular nucleus of the hypothalamus under stress and it stimulates the secretion of adrenocorticotropic hormone (ACTH) from the pituitary gland. ACTH acts on the adrenal cortex and promotes the synthesis of glucocorticoid. This system is called the hypothalamic-pituitary-adrenal (HPA) axis [1]. In the hippocampus, hypothalamus, and pituitary gland, there are two receptors that interact with cortisol: the glucocorticoid receptor and mineralocorticoid receptor. When cortisol secretion is increased, the composition and secretion of CRH and ACTH is controlled through these receptors, which results in the suppression of cortisol secretion (negative feedback) [2]. Dysfunction of the HPA axis causes hippocampal atrophy [3] and it is also related to stress-related diseases such as depression, panic disorder, and post-traumatic stress disorder (PTSD) [4-7]. CRH is a polypeptide consisting of 41 amino acid residues [8]. The CRH family consists of several neuropeptides: CRH, urocortin 1, urocortin 2, and urocortin 3. CRH is primarily responsible for regulating and/or initiating stress responses via activation of the HPA axis [9]. Conversely, urocortins play an indispensable role in the recovery response to stress [9]. CRH released in the brain activates the sympathetic system and stimulates the cardiovascular system [10]. In addition, it stimulates sacral parasympathetic outflow and colonic motility [11]. The dysregulation of CRH increases anxiety and depression [12]. There are two G protein-coupled receptors for CRH: CRH receptor 1 (CRHR1, CRF1 in IUPHAR nomenclature) and CRH receptor 2 (CRHR2, CRF2 in IUPHAR nomenclature). CRHR1 is found at a high density in the brain and pituitary gland, while it is found at a low density in the adrenal gland, ovary, and testis [13-16]. Other than its expression in the brain, CRHR2 is distributed widely throughout peripheral organs such as the heart, skeletal muscle, intestines, and airway epithelium [17-20]. CRH activates both receptors but is more potent at CRHR1. Urocortin 1 can bind both receptors with equal affinity that is 10-fold greater than CRH binding affinity for CRHR1. urocortin and urocortin don’t bind to CRHR1, but CRH, urocortin 2 and urocortin 3 all bind to CRHR2 with equal affinity [21]. The distribution of these receptors and their binding affinities to endogenous ligands in individuals may reflect individual differences in physiological function. Irritable bowel syndrome (IBS) is a prototypic functional gastrointestinal disorder [22] accompanied by visceral hypersensitivity [23], increased gut reactivity [24], and altered central processing [25] in response to various stressors [26]. A previous study demonstrated that mutual and reciprocal interactions between the brain and gut play a major role in the pathophysiology of IBS [27]. In IBS patients, the exogenous administration of CRH induced robust colonic motility [24]. Electrical stimulation of the rectum induced an increase in motility indices in IBS patients and this response was inhibited by the administration of a CRH antagonist [28]. Therefore, dysfunction of CRH signaling is considered to be related to the pathophysiology of IBS. CRH plays a stimulatory role in the stress response through the activation of CRHR1, while the specific actions of urocortin 2 and urocortin 3 on CRHR2 may be important for dampening the stress response [4]. In the brain, CRHR1 stimulation causes anxiety, but CRHR2 stimulation induces anxiolysis. In regard to gut motility, CRHR1 stimulation evokes colonic motility, but CRHR2 stimulation inhibits gastric emptying [12]. From these studies, one of the important determinants of the brain-gut interaction in the stress response of IBS patients is signaling via CRHR1 and CRHR2. The gene encoding CRHR1 is located on chromosome 17q21.31 and has a length of 51.55 Kb and contains 14 exons. The gene encoding CRHR2 is located on chromosome 7p14.3 and has a length 48.19Kb and contains 16 exons. There are many reports on the association between gene variants of CRH receptors and stress-related diseases. In CRHR1, variation of the gene has been found to be a risk factor for depression after childhood maltreatment [29-33]. A polymorphism of CRHR1 was reported to be related to recurrent major depressive disorder (MDD) [34]. In regard to CRHR2, gene variation may affect the risk of PTSD in women by attenuating the stress response and reducing symptoms of the disorder [35]. A polymorphism in the CRHR2 gene was also associated with MDD [36]. In a previous study from our laboratory, we showed that genetic polymorphisms and haplotypes of CRHR1 (rs110402, rs242924, and rs7209436) mediate IBS and related bowel patterns [37]. However, the association between CRHR2 genotypes and IBS has not been investigated. Therefore, we hypothesized that gene polymorphisms and/or haplotypes of CRHR2 may be associated with IBS pathophysiology and negative emotion in IBS patients.

Methods

Subjects

In total, 142 patients (62 males and 80 females) with IBS who were diagnosed at the Department of Psychosomatic Medicine, Tohoku University Hospital, were enrolled in this study (mean age 22.0 ± 0.2 years; range 18–31). Patients with organic diseases were excluded. In addition, 142 healthy volunteers (74 males and 68 females) were recruited at Tohoku University as controls (mean age 22.0 ± 0.2 years; range 19–31). Subjects without any symptoms or signs during a medical interview and physical examination were identified as healthy controls. There was no significant difference in age, sex ratio among the groups. IBS patients were diagnosed according to the Rome III criteria [38]. IBS was defined as recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months associated with two or more of the following symptoms: improvement with defecation, onset associated with a change in the frequency of defecation, and/or onset associated with a change in the form (appearance) of stools. These criteria were fulfilled for the previous 3 months with symptom onset at least 6 months prior to diagnosis. According to the Rome III criteria, IBS was classified as IBS with diarrhea (D), constipation (C), or mixed symptoms of diarrhea and constipation (M). Unclassified IBS patients were classified as IBS-M. All subjects provided written informed consent and this study was approved by the Tohoku University Ethics Committee. Consecutive patients who agreed to participate in this study were enrolled. Two hundred and twenty-two of 284 participants’ DNA samples were previously reported on polymorphisms of the CRHR1 polymorphic region [37]. There are apparently different from the targeted genes in this study.

SNP selection

We used Generic Genome Browser in International HapMap Project (http://hapmap.ncbi.nlm.nih.gov/index.html.en) to search the allele frequency (minor allele frequency > 0.15 in Japanese population). Furthermore, we restricted seven candidate genes, which were selected from single nucleotide polymorphisms (SNPs) for genotyping based on previous literature [35,36,39]. The loci of these SNPs were searched from the dbSNP in the National Center for Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/), and are shown in .

SNPs of the CRHR2 gene examined in this study.

CRHR2 is located on chromosome 7p14.3. The arrows and the numbers in parentheses indicate the locus of each SNP. rs2240403 exists in the fourth exon, but six other SNPs exist in intronic regions. These SNPs had a minor allele frequency of >15% in the Japanese population. A linkage disequilibrium (LD) plot was generated using D′. D′ = 1 indicates complete LD. D′ values < 1.0 are shown in the respective squares for the SNP pairs, with darker shades of red representing higher levels of LD.

Genotyping

Peripheral blood was sampled from the forearm vein of each subject with a heparinized syringe. DNA was then extracted from the lymphocytes using a standard protocol [40]. The concentration of each DNA was diluted to 0.2 μg/μL. Seven SNPs (rs4722999, rs3779250, rs2240403, rs2267710, rs2190242, rs2284217, and rs2284220) in the regulatory region of the CRHR2 gene were genotyped using real-time polymerase chain reaction (PCR). We use the CFX-96 TouchTM Real-time PCR Detection System (Bio-Rad Laboratories, Inc., Tokyo, Japan). PCR amplification was carried out using probe/primer sets for SNP genotyping that were purchased from Applied Biosystems, Tokyo, Japan (set of C1617682310 for rs2240403, C1587286110 for rs2190242, C1596058610 for rs2284217, C1596058010 for rs2284220, C34646010 for rs4722999, C2580980110 for rs3779250, and C1587287110 for rs2267710). PCR amplification was performed using a total volume of 10 μL consisting of 5 μL TaqMan Genotyping Master Mix, 4.4 μL ddH2O, 0.5 μL TaqMan SNP Genotyping Assays, and 0.1 μL DNA. After initial denaturation at 95°C for 10 min, amplification was performed for 40 cycles at 95°C for 15 s and 60°C for 1 min. To determine the positive control, sequence analysis of CRHR2 genes was performed using an ABI 3130 Genetic Analyzer (PE Applied Biosystems, Foster City, CA). All procedures were performed according to the manufacturer's instructions.

Evaluation of psychological state

Participants' psychological states were rated using the Perceived-Stress Scale (PSS; [41], [42]), the State-Trait Anxiety Inventory (STAI; [43], [44]), and the Self-Rating Depression Scale (SDS; [40], [45]). The Japanese versions of STAI, SDS, and PSS have been validated and their reliability has been confirmed [42].

Statistical analysis

The frequencies of genotypes, alleles, and haplotypes of the CRHR2 SNPs were compared between the IBS patients and controls, or between patients with different bowel patterns (normal, constipation, mixed, and diarrhea) using the χ2-test. The effects of variation in CRHR2 SNPs and haplotypes on psychological states between the IBS patients and controls were examined with two-way analysis of variance (ANOVA). The effects of variation in CRHR2 haplotypes on psychological states were examined with one-way ANOVA. Statistical analyses were performed using SPSS Statistics version 21.0 software (IBM, Inc., New York, NY). We used Haploview [46] to determine the LD of the SNPs within the CRHR2 gene and test for Hardy–Weinberg equilibrium. Results are expressed as the mean ± standard error, and a P value < 0.05 was considered to be significant.

Results

In the 284 samples, genotype distributions were in Hardy–Weinberg equilibrium for all seven SNPs. The genotype frequencies of the SNPs in the IBS group and healthy controls are listed in . The allele frequencies of the SNPs in the IBS group, healthy controls, and the subtypes of IBS patients are listed in . P value < 0.05 were indicated in bold. IBS subtype: C, constipation; M, mixed; D, diarrhea. We found that rs4722999 (A) and rs3779250 (B) were significantly associated with IBS in terms of genotype distribution (rs4722999: P = 0.037; rs3779250: P = 0.017) (). For these two SNPs, there was no significant difference in the frequency of the minor allele, but the frequency of the major allele was significantly different.

Difference in genotype of CRHR2 SNPs between the controls and IBS patients.

The SNPs rs4722999 (A) and rs3779250 (B) are shown. The SNPs rs4722999 (P = 0.037) and rs3779250 (P = 0.017, χ2-test) were significantly different in the IBS patients in comparison with the controls. shows the scores of the psychological scales in the controls and IBS patients. There was no significant difference in the test scores for the three psychological scales between the IBS patients and controls. PSS: Perceived Stress Scale, STAI: State Trait anxiety Inventry, SDS: Self-rating Depression Scale. shows that the three psychological scores were significantly different by CRHR2 genotype or group (IBS patients vs. controls). According to PSS in rs2240403, the IBS patients were significantly higher than the controls (P = 0.018), but there was no significant interaction. According to STAI (state) in rs2190242 in males, there was a significant genotype effect (P = 0.046), but there was no significant interaction. According to SDS in rs2190242 in males and rs2240403 in females, there was a significant genotype effect (rs2190242: P = 0.026; rs2240403: P = 0.031), but there was no significant interaction.

Psychological scales and CRHR2 SNPs in IBS patients and controls.

PSS: two-way ANOVA showed that the IBS patients with rs2240403 (P = 0.018) had significantly higher perceived stress scale scores than the controls. STAI (state): rs2190242 in males, genotype effect was significant (P = 0.046). SDS: rs2190242 in males and rs2240403 in females, genotype effect was significant (rs2190242: P = 0.026; rs2240403: P = 0.031). In all scale scores, there was no significant group × genotype interaction. According to the selection criteria, four SNPs (rs4722999, rs3779250, rs2240403, and rs2267710) of CRHR2 with strong D′ (>0.90) were in one linkage block, and two SNPs (rs2284217 and rs2284220) with strong pairwise D′ (>0.90) were in another block (). The selection criteria for haplotypes used in the haplotype analyses were adjacent SNPs with pairwise D′ > 0.90. Haplotype analysis of the IBS group and healthy controls is shown in . We found that three blocks were positively associated with IBS patients (T-C-C-C: P = 0.017; T-C-C-T: P = 0.017; C-T-C-C: P = 0.043). All haplotypes were found more frequently in the IBS patients than in the controls. P value < 0.05 were indicated in bold. We tested whether the psychological scale scores were different by haplotypes using One-way ANOVA. The result was shown in . The psychological scales PSS (A), STAI (state) (B), STAI (trait) (C) and SDS (D) were shown. The carriers with four haplotypes (T-T-T-T, C-T-T-T, C-C-T-T, and T-C-T-T) had significantly lower scores than the others in all psychological scales. The four haplotype carriers were all the same individuals. In addition, in PSS, two haplotypes (C-T-C-T and C-C-C-T) were similarly significant.

Psychological scale scores and CRHR2 haplotypes.

The psychological scales PSS (A), STAI (state) (B), STAI (trait) (C) and SDS (D) were shown. One-way ANOVA showed that the subjects with four haplotypes (T-T-T-T, C-T-T-T, C-C-T-T, and T-C-T-T) had significantly lower score than the others in all psychological scales. The four haplotype carriers were all the same individuals. In addition, in PSS, two haplotypes (C-T-C-T and C-C-C-T) were similarly significant. We tested whether the psychological scale scores were different by haplotypes between the IBS patients and controls using two-way ANOVA. The result was shown in In PSS, group effect (IBS vs. controls) was significant in six haplotypes. However, there was no group effect in other psychological scales. Haplotype effect was significant in all psychological scales. In STAI (trait), there was a significant group × haplotype interaction (P = 0.021). The four haplotype carriers (T-T-T-T, C-T-T-T, C-C-T-T, and T-C-T-T) were all the same individuals. Data without significance were not shown. *: The four haplotype carriers (T-T-T-T, C-T-T-T, C-C-T-T, and T-C-T-T) were all the same individuals.

Discussion

The present study is the first to show an association between IBS and SNPs/haplotypes of the CRHR2 gene in the Japanese population. These data suggest that CRHR2 gene polymorphisms and haplotypes are related to the pathophysiology of IBS. Loss of CRHR2 leads to increased inflammation, delayed healing, and exacerbates the inflammatory insult [47-49]. Akiba et al. reported that peripheral CRHR2 activation induces colonic hyperemia through nitric oxide synthesis without involving prostaglandin synthesis or sensory nerve activation and may protect the colonic mucosa [50]. In a recent study, low grade inflammation was observed in the colonic mucosa of IBS patients [51]. We found that rs4722999 and rs3779250 were positively associated with IBS in terms of genotype frequency. Especially, for both SNPs, CT carriers were observed significantly more often in IBS patients. Ishitobi et al. investigated the association of six SNPs of CRHR2 with MDD and panic disorder [36]. They reported that rs3779250 was associated with MDD, but rs4722999 and the other SNPs were not [36]. In this study, major allele carriers were observed frequently in MDD patients. Similarly, in our study, the frequency of the major allele of rs3779250 was significantly different between the patients and controls. Like IBS, MDD is worsened by psychosocial stress with dysfunction of the HPA axis. From these results, the major allele of rs3779250 may be a risk allele for stress-related diseases. However, the C allele of rs3779250 is observed in approximately 77% of the normal population. Therefore, the increased frequency of the major allele of rs3779250 alone cannot explain the relationship between CRHR2 SNPs and IBS. Further study of other factors (e.g., other genetic polymorphisms) of IBS is required. In this study, there was no significant difference in perceived stress, anxiety, and depression between the IBS patients and controls. Our previous report [52] and the results of others [53] showed that these factors are higher in IBS patients than in controls. By contrast, IBS patients were found to be neither depressive nor anxious in another study from our laboratory [54]. Therefore, IBS patients in this study were psychologically close to normal, but were physically stressed. This notion is supported by the fact that statistical analysis of stress, anxiety, and depression including CRHR2 genotypes with group (IBS patients vs. controls) showed significant differences. The relatively complex association between genotypes and IBS suggests a modifying role for CRHR2 in the pathophysiology of stress. In seven SNP which we selected, six SNPs are in the intronic region. Only rs2240403 is in the exon region, but it is the synonymous SNP which does not cause amino acid substitution. In this study, there were significant differences in the genotype distribution of both groups in rs472299 and rs377950. In addition, there were significant interaction in association between genotype and group (IBS patients vs. controls) in psychological condition in rs2190242 and rs2284220. These SNPs are in intronic region, and the domain is spliced during transcription to mRNA. Therefore those SNPs are less likely to have an influence on the receptor expression directly. However, the SNPs influencing modulation of the psychological condition that is in vicinity of these SNP in the linkage disequilibrium in IBS may exist. We found a haplotype of four SNPs (rs4722999, rs3779250, rs2240403, and rs2267710) and two SNPs (rs2284217 and rs2284220) in strong LD (D′ > 0.90). In this study, SNPs and haplotypes of the CRHR2 gene were significantly different between IBS patients and controls. Sato et al. reported that genetic polymorphisms and T-A-T haplotypes of CRHR1 mediate IBS and related bowel patterns [37]. Guillaume et al. reported that childhood sexual abuse and childhood emotional neglect interacted with CRHR1 and CRHR2 gene polymorphisms, respectively, to modulate adult decision-making in a cohort of suicide attempters [55]. Mahajan et al. reported that the balanced and coordinated expression of CRHR1 and CRHR2 is required for the proper regulation of urocortins in a rodent model of Crohn's colitis [56]. Therefore, haplotypes of both CRHR1 and CRHR2 may be related to the features of IBS. We found that the psychological state varied from CRHR2 genotypes and haplotypes in IBS patients and controls. Especially, we discovered that the group with one of four haplotypes (T-T-T-T, C-T-T-T, C-C-T-T, and T-C-T-T) in CRHR2 showed a significantly lower score in perceived stress, anxiety, and depression in comparison with the group that did not have one of these haplotypes. In these four haplotypes, the common part is the T-T haplotype that consists of the T allele of rs2240403 and T allele of rs2267710. From this finding, it is suggested that having both these T alleles acts protectively against perceived stress and anxiety. To the best of our knowledge, this analysis of these four haplotypes of the CRHR2 gene has not been performed before [35, 36]. This is a novel finding and further studies investigating the association between the T-T haplotype and other stress-related disorders are warranted. This study has several limitations. First, the sample size was relatively small. Particularly, there were small numbers of subjects with the minor allele of rs2240403 and the data had a wide standard error. However, our study has the strength of a higher precision of genome analyses than a genome-wide association study. Moreover, recently published genomic studies [57, 58] contained smaller number of participants than our study. Replication with a larger sample is necessary. Second, all subjects in this study were Japanese. Villafuerte et al. reported that the CRHR2 gene was unlikely to be involved in the genetic liability underlying HPA axis dysfunction and mood disorders [59]. Therefore, there may be ethnic differences in the function of CRHR2. Third, the molecular biologic differences in the CRHR2 gene polymorphisms examined in this study are not known. It is necessary to investigate any changes of function in vivo and behavior associated with the different CRHR2 gene polymorphisms in the future. Despite some limitations, the present study is the first to clarify the possible importance of CRHR2 in the pathophysiology of IBS. In conclusion, our findings support the hypothesis that genetic polymorphisms and haplotypes of CRHR2 are associated with IBS. Further studies of IBS and the CRH system are warranted.
Table 1

Genotypes frequencies for seven CRHR2 SNPs in the IBS patients and controls.

Controls n (%) n = 142IBS Patients n (%) n = 142P value(Control vs. IBS)
Male (n = 74)Female (n = 68)Male (n = 62)Female (n = 80)
rs4722999CC25 (17.6)18 (12.7)15 (10.6)23 (16.2)0.037
CT33 (23.2)34 (23.9)39 (27.5)47 (33.1)
TT16 (11.3)16 (11.3)8 (5.6)10 (7.0)
rs3779250CC27 (19.0)21 (14.8)16 (11.3)28 (19.7)0.017
CT32 (22.5)31 (21.8)38 (26.8)44 (31.0)
TT15 (10.6)16 (11.3)8 (5.6)8 (5.6)
rs2240403CC54 (38.0)37 (26.1)38 (26.8)51 (35.9)0.855
CT18 (12.7)30 (21.1)24 (16.9)27 (19.0)
TT2 (1.4)1 (0.7)0 (0.0)2 (1.4)
rs2267710CC28 (19.7)23 (16.2)20 (14.1)32 (22.5)0.107
CT33 (23.2)32 (22.5)35 (24.6)41 (28.9)
TT13 (9.2)13 (9.2)7 (4.9)7 (4.9)
rs2190242CC25 (17.6)23 (16.2)21 (14.8)31 (21.8)0.518
AC38 (26.8)30 (21.1)30 (21.1)41 (28.9)
AA11 (7.7)15 (10.6)11 (7.7)8 (5.6)
rs2284217GG22 (15.5)22 (15.5)22 (15.5)19 (13.4)0.171
GA37 (26.1)42 (29.6)24 (16.9)46 (32.4)
AA15 (10.6)4 (2.8)16 (11.3)15 (10.6)
rs2284220AA21 (14.8)22 (15.5)23 (16.2)19 (13.4)0.289
AG37 (26.1)41 (28.9)23 (16.2)46 (32.4)
GG16 (11.3)5 (3.5)16 (11.3)15 10.6

P value < 0.05 were indicated in bold.

Table 2

Allele expression in the controls, IBS patients, and IBS subtypes for seven SNPs of the CRHR2 gene.

ControlsIBS PatientsTotal
AllCMD
n = 142n = 142n = 41n = 36n = 65n = 284
rs4722999C allele -321891850
C allele +110124323557234
T allele -43387112081
T allele +99104342545203
rs3779250C allele -311661947
C allele +111126353556237
T allele -484410142092
T allele +9498312245192
rs2240403C allele -320205
C allele +139140413465279
T allele -9189262340180
T allele +5153151325104
rs2267710C allele -261451840
C allele +116128363557244
T allele -5252121624104
T allele +9090292041180
rs2190242C allele -2619411445
C allele +116123373551239
A allele -4852111823100
A allele +9490301842184
rs2284217G allele -1931891450
G allele +123111332751234
A allele -44417102485
A allele +98101342641199
rs2284220A allele -2131891452
A allele +121111332751132
G allele -43427112485
G allele +99100342541199

IBS subtype: C, constipation; M, mixed; D, diarrhea.

Table 3

Perceived stress, depression, and anxiety in the controls and IBS patients.

ControlsIBS PatientsP value
n = 142n = 142
MeanSEMeanSE
PSS26.70.8280.70.203
STAI (state)44.10.845.20.80.361
STAI (trait)47.90.947.50.90.739
SDS39.40.740.60.60.23

PSS: Perceived Stress Scale, STAI: State Trait anxiety Inventry, SDS: Self-rating Depression Scale.

Table 4

Haplotype frequencies of the IBS patients and controls in the CRHR2 gene.

HaplotypeControl—FreqCase—FreqP value
rs4722999—rs2267710
TTCT0.6410.6200.806
CCCC0.7540.8520.052
CCTC0.3590.3730.902
TTCC0.4790.5920.074
TCCC0.4790.6270.017
CTCT0.4150.5140.122
TTTC0.1550.2110.283
TTTT0.1480.1900.429
CTTT0.1480.1900.429
CCTT0.1480.1900.429
TCCT0.4790.6270.017
TCTT0.1480.1900.429
CTTC0.1550.2110.283
CTCC0.4370.5630.043
TCTC0.1760.2250.374
CCCT0.4150.5070.153
rs2284217—rs2284220
GA0.8520.7820.167
AG0.6900.7040.897
AA0.5420.4930.476
GG0.5630.4860.235

P value < 0.05 were indicated in bold.

Table 5

Psychological state and CRHR2 SNPs in IBS patients and controls.

HaplotypeIBS vs. controls (P value)haplotype effect (P value)group-haplotype interaction (P value)
PSS
rs4722999—rs2267710
TTTC0.0470.035ns
TTTT*0.0410.005ns
CTTT*0.0410.005ns
CCTT*0.0410.005ns
TCTT*0.0410.005ns
CTTC0.0470.035ns
CTCCns0.041ns
CCCTns0.014ns
STAI (state)
rs4722999—rs2267710
TTTCns0.035ns
TTTT*ns0.020ns
CTTT*ns0.020ns
CCTT*ns0.020ns
TCTT*ns0.020ns
CTTCns0.035ns
STAI (trait)
rs4722999—rs2267710
TTTT*ns0.020ns
CTTT*ns0.020ns
CCTT*ns0.020ns
TCTT*ns0.020ns
rs2284217—rs2284220
GGnsns0.021
SDS
rs4722999—rs2267710
TTTT*ns0.012ns
CTTT*ns0.012ns
CCTT*ns0.012ns
TCTT*ns0.012ns

Data without significance were not shown.

*: The four haplotype carriers (T-T-T-T, C-T-T-T, C-C-T-T, and T-C-T-T) were all the same individuals.

  57 in total

Review 1.  Sensitivity to stress: dysregulation of CRF pathways and disease development.

Authors:  Tracy L Bale
Journal:  Horm Behav       Date:  2005-03-17       Impact factor: 3.587

Review 2.  Physiology and neurobiology of stress and adaptation: central role of the brain.

Authors:  Bruce S McEwen
Journal:  Physiol Rev       Date:  2007-07       Impact factor: 37.312

3.  [A study on a self-rating depression scale (author's transl)].

Authors:  K Fukuda; S Kobayashi
Journal:  Seishin Shinkeigaku Zasshi       Date:  1973-10

4.  Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention.

Authors:  H Mertz; V Morgan; G Tanner; D Pickens; R Price; Y Shyr; R Kessler
Journal:  Gastroenterology       Date:  2000-05       Impact factor: 22.682

5.  Correlation between DQB1 genetic polymorphism and genetic susceptibility in patients diagnosed with irritable bowel syndrome with diarrhea.

Authors:  F Yu; S Huang; F Zhou; Q Luo; X Xie; C Zheng
Journal:  Genet Mol Res       Date:  2014-12-04

Review 6.  Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation.

Authors:  Shin Fukudo
Journal:  J Gastroenterol       Date:  2007-01       Impact factor: 7.527

7.  Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extension.

Authors:  Guilherme Polanczyk; Avshalom Caspi; Benjamin Williams; Thomas S Price; Andrea Danese; Karen Sugden; Rudolf Uher; Richie Poulton; Terrie E Moffitt
Journal:  Arch Gen Psychiatry       Date:  2009-09

8.  Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene.

Authors:  Rebekah G Bradley; Elisabeth B Binder; Michael P Epstein; Yilang Tang; Hemu P Nair; Wei Liu; Charles F Gillespie; Tiina Berg; Mark Evces; D Jeffrey Newport; Zachary N Stowe; Christine M Heim; Charles B Nemeroff; Ann Schwartz; Joseph F Cubells; Kerry J Ressler
Journal:  Arch Gen Psychiatry       Date:  2008-02

9.  Negative life events and corticotropin-releasing-hormone receptor1 gene in recurrent major depressive disorder.

Authors:  Zhongchun Liu; Wanhong Liu; Lihua Yao; Can Yang; Ling Xiao; Qirong Wan; Kai Gao; Huiling Wang; Fan Zhu; Gaohua Wang; Zheman Xiao
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

10.  A genetic association study of single nucleotide polymorphisms in GNβ3 and COMT in elderly patients with irritable bowel syndrome.

Authors:  Yuezhi Wang; Zhengyu Wu; Hui Qiao; Yu Zhang
Journal:  Med Sci Monit       Date:  2014-07-19
View more
  8 in total

Review 1.  Don't stress about CRF: assessing the translational failures of CRF1antagonists.

Authors:  Samantha R Spierling; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

2.  Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response.

Authors:  Alexa Orand; Bruce Naliboff; Malin Gadd; Wendy Shih; Tiffany Ju; Angela P Presson; Emeran A Mayer; Lin Chang
Journal:  Psychoneuroendocrinology       Date:  2016-07-19       Impact factor: 4.905

Review 3.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

4.  Considering Sex as a Biological Variable in Basic and Clinical Studies: An Endocrine Society Scientific Statement.

Authors:  Aditi Bhargava; Arthur P Arnold; Debra A Bangasser; Kate M Denton; Arpana Gupta; Lucinda M Hilliard Krause; Emeran A Mayer; Margaret McCarthy; Walter L Miller; Armin Raznahan; Ragini Verma
Journal:  Endocr Rev       Date:  2021-05-25       Impact factor: 25.261

Review 5.  The Increased Level of Depression and Anxiety in Irritable Bowel Syndrome Patients Compared with Healthy Controls: Systematic Review and Meta-analysis.

Authors:  Changhyun Lee; Eunyoung Doo; Ji Min Choi; Seung-Ho Jang; Han-Seung Ryu; Ju Yup Lee; Jung Hwan Oh; Jung Ho Park; Yong Sung Kim
Journal:  J Neurogastroenterol Motil       Date:  2017-07-30       Impact factor: 4.924

6.  Evidence-based clinical practice guidelines for irritable bowel syndrome 2020.

Authors:  Shin Fukudo; Toshikatsu Okumura; Masahiko Inamori; Yusuke Okuyama; Motoyori Kanazawa; Takeshi Kamiya; Ken Sato; Akiko Shiotani; Yuji Naito; Yoshiko Fujikawa; Ryota Hokari; Tastuhiro Masaoka; Kazuma Fujimoto; Hiroshi Kaneko; Akira Torii; Kei Matsueda; Hiroto Miwa; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-02-04       Impact factor: 7.527

Review 7.  Irritable bowel syndrome and microbiome; Switching from conventional diagnosis and therapies to personalized interventions.

Authors:  Pouyan Ghaffari; Saeed Shoaie; Lars K Nielsen
Journal:  J Transl Med       Date:  2022-04-11       Impact factor: 5.531

Review 8.  Gut Microbial Metabolites and Biochemical Pathways Involved in Irritable Bowel Syndrome: Effects of Diet and Nutrition on the Microbiome.

Authors:  Shanalee C James; Karl Fraser; Wayne Young; Warren C McNabb; Nicole C Roy
Journal:  J Nutr       Date:  2020-05-01       Impact factor: 4.798

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.